Actively Recruiting
Evaluating Safety and Activity of Cevostamab and Elranatamab Combination in Adults With Relapsed or Refractory Multiple Myeloma
Led by Genentech, Inc. · Updated on 2026-10-06
120
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of combining two drugs, cevostamab and elranatamab, in adults with relapsed or refractory multiple myeloma. This Phase Ib trial aims to determine the recommended dose and regimen for further study. The study includes a safety lead-in stage followed by an expansion phase to further assess the treatment combination. Participants receive cevostamab through intravenous infusion and elranatamab as a subcutaneous injection, starting with step-up dosing in a pre-phase. After this, elranatamab is given at the assigned dose as a subcutaneous injection until the disease progresses or unacceptable side effects occur. Cevostamab is given by infusion until disease progression, unacceptable toxicity, or up to one year of treatment, whichever comes first. Some participants may receive elranatamab alone following the same dosing schedule. During the study, participants are monitored for adverse events and their response to treatment using established criteria for multiple myeloma. Blood samples are collected to measure drug concentrations and immune responses. The study lasts approximately 36 months, during which researchers also assess survival, response duration, and time to response. Safety and effectiveness data guide recommendations for future treatment regimens.
CONDITIONS
Brief Title
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Research Team
G
GO43979 https://forpatients.roche.com/ No attachments to email below.
F
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here